In the first trading session on January 23, Cipla's shares surged 7% to reach a 52-week high of Rs 1,409, just one day after the business reported a solid third-quarter performance across all major metrics of profit, revenue, and profitability.

Despite a remarkable loss of Rs 194.8 crore, the company's net profit for the quarter increased 32.7 percent year over year to Rs 1,049 crore. A 14.2 percent year-over-year gain in sales to Rs 6,544 crore during the October–December period also contributed to the bottom-line growth.

Market expansion was mainly widespread as the business recorded its highest-ever North American revenues of $230 million, up 18% year over year. Sales from South Africa increased by about 10% to Rs 603 crore, while the India business expanded by almost 12% to Rs 2,859 crore.

Solid performance in branded prescription, trade generics, and consumer health drove the growth in the India business, while solid demand in the base business and ongoing momentum in key assets, together with some year-end buying, supported the growth in North America.

In local currency terms, the firm in South Africa also benefited from the rise in income. Positive traction in prescription, over-the-counter, and tender data supported this performance.

Cipla's shares were trading at Rs 1,390.35 on the NSE at 9:28 a.m. Additionally, the company's operating margins increased to 26.5 percent in Q3 from 24.2 percent in Q2 due to the outstanding quarterly performance. A third inhalation asset and the generic version of the asthama medication, Symbicort, were also filed in Q3 by the pharmaceutical company. In FY25, it also intends to introduce four peptides.